The CDC last December dropped its longstanding recommendation that all newborns get a hepatitis B vaccine dose within 24 hours of birth, shifting to maternal screening and selective vaccination instead. Two new JAMA Pediatrics modeling studies estimate that delaying or narrowing birth-dose coverage could cause 69 to 628 additional infections in targeted scenarios, and up to 29 to 50 additional deaths plus $16.4 million to nearly $30 million in added health care costs.

The Move

• For review: the Centers for Disease Control and Prevention changed guidance first issued in 1991, moving away from universal newborn hepatitis B vaccination at birth.

• The revised approach, based on ACIP recommendations, emphasizes screening pregnant women for hepatitis B and vaccinating at birth mainly infants born to mothers who test positive or are unscreened.

• Two separate modeling studies published in JAMA Pediatrics Monday are the first estimates of the policy shift's potential consequences.

Why It Matters for Care

• At the bedside, the key implication is simple: delaying the birth dose increases preventable infection risk even when later vaccination rates are high.

• In one model of roughly 3.6 million U.S. births, delaying the first dose to 2 months still led to 90 additional acute infections, 76 chronic infections, 29 deaths and $16.4 million in added costs.

• Delaying to 12 months led to 190 additional infections, 50 deaths and nearly $30 million in extra spending.

• Infants are uniquely vulnerable: about 90% of babies infected with hepatitis B develop chronic disease, versus about 5% of adults, and 1 in 4 infected at birth die prematurely.

Between the Lines

• The policy rests on the idea that maternal screening can replace universal prophylaxis, but that depends on screening actually happening and results being correctly acted on.

• That assumption is shaky: a 2023 March of Dimes report found 500,000 pregnant women in the U.S. were not screened for hepatitis B.

• Critics including the American Academy of Pediatrics argue the CDC and ACIP traded a simple, highly reliable standing practice for a more failure-prone system requiring testing, documentation, communication and follow-up.

• Second-order effect: once universal birth-dose guidance is softened federally, hospitals, clinicians and parents may see more opt-outs and more variation in newborn protocols.

What to Watch

• Whether the CDC or HHS revisits the recommendation in light of the new modeling data and pushback from pediatric and infectious disease groups.

• Whether ACIP takes up hepatitis B policy again, especially as implementation gaps around prenatal screening and newborn vaccination become clearer.

• How states, hospital systems and professional societies respond, since federal vaccine guidance is not itself legally binding and local schedules can diverge.

• Whether universal newborn vaccination remains the de facto standard in nurseries as groups like the AAP continue recommending a birth dose for all infants.

Source: Straight Arrow News